
Partnership to scale cell-based mRNA platform
Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding (MoU) to jointly advance the industrialisation and scale-up of Sensible’s first-in-class cell-based platform for the design, optimisation, and manufacturing of high-quality mRNA. The collaboration aims to enable clinical-grade production of cell-based mRNA by 2026 and unlock the “next… Read More
